De Burlo Group Inc Bristol Myers Squibb CO Transaction History

De Burlo Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $488,012 - $545,673	-8,430 Reduced 44.49%	10,520 $610,000
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $19,113 - $21,222	-300 Reduced 1.56%	18,950 $1.21 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $36,140 - $40,991	-550 Reduced 2.78%	19,250 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $6,848 - $8,109	100 Added 0.51%	19,800 $1.42 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $315 - $186,490	-2,427 Reduced 10.97%	19,700 $1.4 Million
Q2 2022 Aug 11, 2022	BUY	$72.62 - $79.98 $107,259 - $118,130	1,477 Added 7.15%	22,127 $1.7 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $190,588 - $228,532	-3,100 Reduced 13.05%	20,650 $1.51 Million
Q4 2021 Jan 28, 2022	SELL	$53.63 - $62.52 $193,068 - $225,072	-3,600 Reduced 13.16%	23,750 $1.48 Million
Q3 2021 Nov 09, 2021	BUY	$59.17 - $69.31 $5,917 - $6,931	100 Added 0.37%	27,350 $1.62 Million
Q1 2021 May 06, 2021	SELL	$59.34 - $66.74 $29,670 - $33,370	-500 Reduced 1.8%	27,250 $1.72 Million
Q3 2020 Nov 05, 2020	BUY	$57.43 - $63.64 $1.59 Million - $1.77 Million	27,750 New	27,750 $1.67 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of De Burlo Group Inc, based on Form 13F filings with the SEC.

Stay updated on De Burlo Group Inc with notifications on news.